Yes, P-III trial results will (or should) confirm and compare product efficacy.
But a dodgy or unproven treatment is just that. Does not matter whether its in India, Russia, Tajikistan or Australia. And I'm taking a guess flogging nostrums will not support MSBs target SP or MKT cap.
Probably be far less expensive in Tajikistan anyway. I hear the somoni/AUD exchange rate is quite good these days
Yes, P-III trial results will (or should) confirm and compare...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.10 |
Change
-0.025(2.22%) |
Mkt cap ! $1.261B | |||
| Open | High | Low | Value | Volume |
| $1.14 | $1.16 | $1.10 | $2.587M | 2.307M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 22 | 160357 | $1.10 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.11 | 70396 | 12 |
View Market Depth
| Last trade - 10.55am 29/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |